|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.2 USD | +0.65% |
|
+8.58% | -20.82% |
| Mar. 12 | LifeStance Health Appoints Teresa DeLuca to Its Board of Directors | CI |
| Mar. 06 | Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating | MT |
LifeStance Health Group, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 1,055.67 million compared to USD 859.54 million a year ago. Net loss was USD 186.26 million compared to USD 215.56 million a year ago.
Basic loss per share from continuing operations was USD 0.51 compared to USD 0.61 a year ago. Diluted loss per share from continuing operations was USD 0.51 compared to USD 0.61 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.82% | 2.37B | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +11.62% | 29.59B | |
| -12.71% | 16.73B | |
| -2.28% | 16.36B | |
| -2.63% | 14.92B | |
| -31.58% | 11.77B | |
| +0.05% | 11.72B | |
| +27.44% | 11.71B |
LIFESTANCE HEALTH GROUP, INC. 
